Alnylam’s Amvuttra Market May See Tenfold Increase After Phase III Win
The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.
The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.